Is Messenger RNA Patent-Eligible?
Amid ongoing patent disputes over the mRNA platform, a significant scientific question remains unanswered: whether mRNA itself even is patent eligible.
pfizer and biontech covid vaccine
-
Read more: Is Messenger RNA Patent-Eligible? -
Read more: COVID-19 Vaccine Patent Infringement? The Battle Between Moderna and Pfizer/BioNTech Continues COVID-19 Vaccine Patent Infringement? The Battle Between Moderna and Pfizer/BioNTech Continues
An explanation of the key patents at stake in the intellectual property dispute between Moderna and Pfizer/BioNTech over COVID-19 vaccines.
-
Read more: Why Do Differences in Clinical Trial Design Make It Hard to Compare COVID-19 Vaccines? Why Do Differences in Clinical Trial Design Make It Hard to Compare COVID-19 Vaccines?
Because of differences in how they were tested in clinical trials, it is difficult to make apples-to-apples comparisons for COVID-19 vaccines.
-
Read more: “Stick to the Science”? FDA, Ethics, and Pandemics “Stick to the Science”? FDA, Ethics, and Pandemics
This post reflects on the ethical implications of FDA’s use of its emergency powers, and suggests opportunities for greater accountability moving forward.
-
Read more: What’s the Difference Between Vaccine Approval (BLA) and Authorization (EUA)? What’s the Difference Between Vaccine Approval (BLA) and Authorization (EUA)?
A Biologics License Application, or BLA, is FDA’s standard “full approval” mechanism for biological products, including therapeutics and vaccines.
-
Read more: The Legality and Feasibility of COVID-19 Vaccine Mandates for Children The Legality and Feasibility of COVID-19 Vaccine Mandates for Children
Now that children over the age of 12 can get vaccinated against COVID-19, will immunization become a requirement for returning to school?
-
Read more: How the Government Can Prevent Individuals from Using Wealth to Cut the Vaccine Line How the Government Can Prevent Individuals from Using Wealth to Cut the Vaccine Line
There are several ways government officials can combat the wealth problem without sacrificing the speed at which vaccines are administered.
-
Read more: From 9/11 to COVID-19: A Brief History of FDA Emergency Use Authorization From 9/11 to COVID-19: A Brief History of FDA Emergency Use Authorization
The history of EUA involves fundamental questions about the role of public officials, scientific expertise, and administrative norms in times of crisis.
-
Read more: Challenges in COVID-19 Vaccine Rollout: Lessons from the UK Challenges in COVID-19 Vaccine Rollout: Lessons from the UK
The U.S. can and should cautiously assess the U.K.’s vaccination strategy to avoid challenges that may impede its ability to control the virus.
